Clinical Trial Update: Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating sintilimab with IBI305 plus pemetrexed and cisplatin for EGFR-mutant, locally advanced or metastatic non-squamous non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Non-squamous Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• IBI305 (bevacizumab biosimilar)
• Pemetrexed (pemetrexed)
• Sintilimab (sintilimab)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED